Overview

NI-0401 in Active Crohn's Disease

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

NovImmune SA

Treatments:

Muromonab-CD3